ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
A Prospective Study of the Correlation Between Time in Range and Incidence of Diabetic Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficient Synthesis of Glucovanillin and Elucidation of Its Molecular Mechanisms in Ameliorating T2DM via Core Target Modulation and α-Glucosidase Inhibition.Molecules (Basel, Switzerland) · 2026Article
- Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes.Diabetes, obesity & metabolism · 2026Review
- The atherogenic index of plasma predicts long-term outcomes in patients with severe coronary artery calcification undergoing rotational atherectomy: a machine learning-based cohort study.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the correlation between time in range (TIR) and the risk of cardiovascular autonomic neuropathy (CAN) development in patients with Type 2 diabetes mellitus (T2DM). Patients and Methods: This prospective cohort study enrolled patients with type 2 diabetes mellitus (T2DM) hospitalized and followed at the Department of Endocrinology, Hefei Hospital of Anhui Medical University, between September 2020 and July 2024. All participants underwent standardized cardiovascular autonomic neuropathy (CAN) assessment via the Ewing test, and time in range (TIR) was derived from baseline continuous glucose monitoring (CGM) data. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CAN incidence, adjusted for relevant covariates. Results: Over a median follow-up of 25.0 months, 123 of 196 participants (62.8%) were diagnosed with CAN. The CAN group exhibited longer diabetes duration, lower time in range (TIR) and body mass index (BMI), higher time above range (TAR), mean glucose (MG), urinary albumin-to-creatinine ratio (UACR), and higher insulin use rates. Participants with low TIR were older, had longer diabetes duration, and displayed: 1. Higher fasting plasma glucose (FPG), HbA1c, and LDL-C levels; 2. Elevated glycemic variability (MAGE, CV, LAGE, SD, MG, TAR) via continuous glucose monitoring (CGM); 3. Greater likelihood of insulin therapy. All differences were statistically significant (P < 0.05). Multivariable Cox regression analyses, adjusted for key covariates (eg, age, HbA1c, insulin use), demonstrated an inverse association between TIR and CAN incidence. Conclusion: Lower TIR is an independent risk factor for CAN in T2DM patients, with higher TIR levels associated with reduced CAN risk (P < 0.05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.